spacer
home > ebr > summer 2017 > complex characters
PUBLICATIONS
European Biopharmaceutical Review

Complex Characters

Oligonucleotides are biopolymers consisting of modified ribonucleotide or deoxynucleotide monomer units. Since they play such a critical role at the human cellular level, they are being developed by several biopharmaceutical organisations as potential therapies and vaccines and are considered to be their own unique modality, distinct from traditional small molecule drugs and biologics.

The FDA has approved a number of these biopolymers, including fomivirsen, pegaptanib and mipomersen, primarily antisense oligonucleotides (ASOs), with several more on the way. In Europe, the Committee for Medicinal Products for Human Use, a division of the EMA, has recently recommended nusinersen for approval. n 100 oligonucleotide drugs progressing through the development pipeline, designed to target diseases and rare genetic disorders, including Huntington’s disease, asthma and certain types of cancer, as well as vaccines for the Ebola, Zika and influenza viruses.

Brief Background

Messenger RNA (mRNA) is a type of oligonucleotide that is critical to the translation of genetic sequence information of DNA into the specific amino acid array of proteins manufactured in the ribosomes of a cell’s cytoplasm. In eukaryote human cells, mRNA consists of several distinct regions. This naturally occurring sequence is known as the sense sequence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jon S Kauffman, PhD, is Senior Director of Biopharmaceutical Services and Method Development and Validation at Eurofins Lancaster Laboratories. With more than 25 years of analytical testing experience, he oversees departments responsible for developing and validating methods and performing analysis of clinical and commercial samples for stability and release purposes. Jon earned a doctorate in chemistry from the University of Delaware, US.
spacer
Jon S Kauffman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

York Health Economics Consortium offers an updated training event

Health economics evidence is a key element in much health services research and particularly in health technology assessments, including submissions for NICE single technology appraisals. Identifying economic evidence to inform submissions involves searches in a range of databases and uses a variety of strategies.
More info >>

White Papers

Running Smarter Trials With Data-Driven Monitoring

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>

 
Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement